The rationale for integrating GM-CSF and IL-2 with dinutuximab is to enhance antibody-dependent cellular cytotoxicity (ADCC), primarily by amplifying granulocyte and NK cell counts and activation, which constitute the primary mechanism of dinutuximab-induced anti-neuroblastoma immune reactions. The gene discussed is CSF2; the disease is neuroblastoma.